Javascript must be enabled to continue!
Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020
View through CrossRef
Introduction: We assessed best available data on access and delivery of acute stroke unit (SU) care, intravenous thrombolysis (IVT) and endovascular treatment (EVT) in the European region in 2019 and 2020. Patients and methods: We compared national data per number of inhabitants and per 100 annual incident first-ever ischaemic strokes (AIIS) in 46 countries. Population estimates and ischaemic stroke incidence were based on United Nations data and the Global Burden of Disease Report 2019, respectively. Results: The estimated mean number of acute SUs in 2019 was 3.68 (95% CI: 2.90–4.45) per one million inhabitants (MIH) with 7/44 countries having less than one SU per one MIH. The estimated mean annual number of IVTs was 21.03 (95% CI: 15.63–26.43) per 100,000 and 17.14% (95% CI: 12.98–21.30) of the AIIS in 2019, with highest country rates at 79.19 and 52.66%, respectively, and 15 countries delivering less than 10 IVT per 100,000. The estimated mean annual number of EVTs in 2019 was 7.87 (95% CI: 5.96–9.77) per 100,000 and 6.91% (95% CI: 5.15–8.67) of AIIS, with 11 countries delivering less than 1.5 EVT per 100,000. Rates of SUs, IVT and EVT were stable in 2020. There was an increase in mean rates of SUs, IVT and EVT compared to similar data from 2016. Conclusion: Although there was an increase in reperfusion treatment rates in many countries between 2016 and 2019, this was halted in 2020. There are persistent major inequalities in acute stroke treatment in the European region. Tailored strategies directed to the most vulnerable regions should be prioritised.
SAGE Publications
Diana Aguiar de Sousa
Arlene Wilkie
Bo Norrving
Chris Macey
Claudio Bassetti
Cristina Tiu
Greg Roth
Grethe Lunde
Hanne Christensen
Jens Fiehler
Francesca Romana Pezzella
Martin Dichgans
Melinda B Roaldsen
Peter Kelly
Robert Mikulik
Simona Sacco
Valeria Caso
Urs Fischer
Entela Basha
Nune Yeghiazaryan
Stefan Kiechl
Rana Shiraliyeva
Peter Vanacker
Marija Bender
Mihael Emilov Tsalta-Mladenov
Hrvoje Budincevic
Ales Tomek
Georgios Kaponides
Helle Klingenberg Iversen
Jürgen Faiss
Janika Kõrv
Tiina Sairanen
Sibon Igor
Alexander Tsiskaridze
George Ntaios
Georgios Tsivgoulis
Laszlo Szapary
Bjorn Logi Thorarinsson
Joe Harbison
Natan M. Bornstein
Danilo Toni
Jashari Fisnik
Kunduz Karbozova
Evija Miglane
Jatužis Dalius
Dirk Droste
Maria Mallia
Erakovic Jevto
Anita Arsovska
Annette Fromm
Adam Kobayashi
Elsa Azevedo
Stanislav Groppa
Tiu Cristina
Alla Guekht
Zeljko Zivanovic
Vladimir Nosal
Bojana Zvan
Elena López-Cancio
Natàlia Pérez de la Ossa
Bo Norrving
Krassen Nedeltchev
Bert Vrijhoef
Mehmet Akif Topcuoglu
Yuriy Flomin
Rubina Ahmed
Andrey Shelesko
Mentor Petrela
Lina Zubalova
Rovshan Hasanov
Sylvie De Raedt
Mahmutbegović Nevena
Silva Peteva Andonova
Zdravka Poljakovic
Ondrej Skoda
Johnsen Søren Paaske
Prof. Dr. med. Helmuth Steinmetz
Janika Kõrv
Tiina Sairanen
Sablot Denis
Nino Lobjanidze
Haralambos Milionis
Panagiotis Mitsias
Gabor Tarkanyi MD
Marianne Elisabeth Klinke
David Tanne
Petraglia Luca
Boshnjaku Dren
Dzhamal Turgumbaev
Karelis Guntis
Jatužis Dalius
Dirk Droste
Debeljevic Mladen
Anita Arsovska
Martin Kurz
Czlonkowska Anna
Zota Eremei
Terecoasa Elena Oana
Mikhail Martinov
Dejana Jovanović
Zuzana Gdovinova
Bojana Zvan
Elena López-Cancio
Pol Camps Renom
Vincent Kwa
Ethem Murat Arsava
Maryna Gulyayeva
Michelle Dharmasiri
Entela Basha
Eleni Korompoki
Konstantinos Vadikolias
Daniel Bereczki MD
Anna Bryndis Einarsdottir
Blyta Afrim
Elmira Mamytova
Jurjans Kristaps
Rastenytė Daiva
Oana Costache
Roganovic Milovan
Annette Fromm
Karlinski Michal
Gasnas Alexandru
Tuta Sorin
Mikhail Fidler
Ranko Raičević
Marjan Zaletel
Mar Castellanos
Manuel Gómez-Choco
Hadiye Sirin
Dmytro Lebedynets
Jattinder Khaira
Eugen Enesi
David Sahakyan
Ayten Mammadbayli
Robin Lemmens
Smajlović Dževdet
Mihael Emilov Tsalta-Mladenov
Hrvoje Budincevic
Martin Sramek
med. Darius Nabavi
Riina Vibo
Daniel Strbian
Rahim Aliyev
Robert Mikulik
David Ozretic
Miloslav Rocek
Stavngaard Trine
Prof. Dr. med. Claus Zimmer
Vladislav Malikov
Kimmo Lappalainen
Berge Jerome
Mirza Khinikadze
Elias Brountzos
Vilhjalmur Vilmarsson
Kupcs Karlis
Kurminas Marius
Michel Hoffmann
Reuben Grech
Mitric Marija
Gaute Kjellevold Wathle
Poncyljusz Wojciech
Crivorucica Igor
Dorobat Bogdan
Viktor Till
Andrej Klepanec
Zoran Milosevic
Juan Macho
Ozcan Ozdemir
Dmytro Shchehlov
Damgaard Dorte
Peter Hermanek
Lela Sturua
Olga Siskou
Georgios Tsivgoulis
Carmit Libruder
Bent Indredavik
Elsa Azevedo
Manole Elena
Milija Mijajlović
Peter Turcani
Bo Norrving
Leo Bonati
Paul Nederkoorn
Muhammed Ertuğrul Eğin
Dmytro Samofalov
Ose Diana
Gaidelytė Rita
Dirk Droste
Title: Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020
Description:
Introduction: We assessed best available data on access and delivery of acute stroke unit (SU) care, intravenous thrombolysis (IVT) and endovascular treatment (EVT) in the European region in 2019 and 2020.
Patients and methods: We compared national data per number of inhabitants and per 100 annual incident first-ever ischaemic strokes (AIIS) in 46 countries.
Population estimates and ischaemic stroke incidence were based on United Nations data and the Global Burden of Disease Report 2019, respectively.
Results: The estimated mean number of acute SUs in 2019 was 3.
68 (95% CI: 2.
90–4.
45) per one million inhabitants (MIH) with 7/44 countries having less than one SU per one MIH.
The estimated mean annual number of IVTs was 21.
03 (95% CI: 15.
63–26.
43) per 100,000 and 17.
14% (95% CI: 12.
98–21.
30) of the AIIS in 2019, with highest country rates at 79.
19 and 52.
66%, respectively, and 15 countries delivering less than 10 IVT per 100,000.
The estimated mean annual number of EVTs in 2019 was 7.
87 (95% CI: 5.
96–9.
77) per 100,000 and 6.
91% (95% CI: 5.
15–8.
67) of AIIS, with 11 countries delivering less than 1.
5 EVT per 100,000.
Rates of SUs, IVT and EVT were stable in 2020.
There was an increase in mean rates of SUs, IVT and EVT compared to similar data from 2016.
Conclusion: Although there was an increase in reperfusion treatment rates in many countries between 2016 and 2019, this was halted in 2020.
There are persistent major inequalities in acute stroke treatment in the European region.
Tailored strategies directed to the most vulnerable regions should be prioritised.
Related Results
Iranian stroke model-how to involve health policymakers
Iranian stroke model-how to involve health policymakers
Stroke in Iran, with more than 83 million population, is a leading cause of disability and mortality in adults. Stroke has higher incidence in Iran comparing the global situation a...
HIPERTENSI, USIA, JENIS KELAMIN DAN KEJADIAN STROKE DI RUANG RAWAT INAP STROKE RSUD dr. M. YUNUS BENGKULU
HIPERTENSI, USIA, JENIS KELAMIN DAN KEJADIAN STROKE DI RUANG RAWAT INAP STROKE RSUD dr. M. YUNUS BENGKULU
Hypertension, Age, Sex, and Stroke Incidence In Stroke Installation Room RSUD dr. M. Yunus BengkuluABSTRAKStroke adalah gejala-gejala defisit fungsi susunan saraf yang diakibatka...
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
According to epidemiological studies, the leading cause of morbidity, disability and mortality are cerebrovascular diseases, in particular ischemic and hemorrhagic strokes. In rece...
Dyselectrolytaemia in Acute Stroke Patients, an Observational Study
Dyselectrolytaemia in Acute Stroke Patients, an Observational Study
Background: There are many studies on stroke, its associated conditions and their effect on stroke patients outcome, but a few studies on dyselectrolytaemia in stroke patients has...
Clinical Features, Risk Factors and Hospital Mortality of Acute Stroke Patients
Clinical Features, Risk Factors and Hospital Mortality of Acute Stroke Patients
Background: Stroke is a leading cause of mortality and disability worldwide. To prevent complications and permanent defects, early diagnosis, distinguishing the type and risk facto...
Heterogeneity among women with stroke: health, demographic and healthcare utilization differentials
Heterogeneity among women with stroke: health, demographic and healthcare utilization differentials
Abstract
Background
Although age specific stroke rates are higher in men, women have a higher lifetime risk and are more likely to die from a stroke...
Degeneration of structural brain networks is associated with cognitive decline after ischaemic stroke
Degeneration of structural brain networks is associated with cognitive decline after ischaemic stroke
Abstract
Over one third of stroke patients have long-term cognitive impairment. The likelihood of cognitive dysfunction is poorly predicted by the location or size o...
Promising Strategies for the Development of Advanced In Vitro Models with High Predictive Power in Ischaemic Stroke Research
Promising Strategies for the Development of Advanced In Vitro Models with High Predictive Power in Ischaemic Stroke Research
Although stroke is one of the world’s leading causes of death and disability, and more than a thousand candidate neuroprotective drugs have been proposed based on extensive in vitr...

